ATE555215T1 - Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert - Google Patents

Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert

Info

Publication number
ATE555215T1
ATE555215T1 AT06774185T AT06774185T ATE555215T1 AT E555215 T1 ATE555215 T1 AT E555215T1 AT 06774185 T AT06774185 T AT 06774185T AT 06774185 T AT06774185 T AT 06774185T AT E555215 T1 ATE555215 T1 AT E555215T1
Authority
AT
Austria
Prior art keywords
correlates
molecular
represent
result
neoplastic disease
Prior art date
Application number
AT06774185T
Other languages
English (en)
Inventor
David Hoon
Joseph Kim
Original Assignee
Wayne John Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne John Cancer Inst filed Critical Wayne John Cancer Inst
Application granted granted Critical
Publication of ATE555215T1 publication Critical patent/ATE555215T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06774185T 2005-06-27 2006-06-27 Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert ATE555215T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69438305P 2005-06-27 2005-06-27
PCT/US2006/025165 WO2007002746A2 (en) 2005-06-27 2006-06-27 Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome

Publications (1)

Publication Number Publication Date
ATE555215T1 true ATE555215T1 (de) 2012-05-15

Family

ID=37596015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06774185T ATE555215T1 (de) 2005-06-27 2006-06-27 Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert

Country Status (7)

Country Link
US (1) US20070031867A1 (de)
EP (1) EP1898803B1 (de)
JP (1) JP2009501004A (de)
AT (1) ATE555215T1 (de)
AU (1) AU2006261671A1 (de)
CA (1) CA2617755A1 (de)
WO (1) WO2007002746A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065626A1 (en) * 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
JP5652809B2 (ja) 2009-03-02 2015-01-14 株式会社ルネッサンス・エナジー・インベストメント 癌組織由来細胞塊およびその調製法
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
JP5774496B2 (ja) * 2010-01-19 2015-09-09 株式会社ルネッサンス・エナジー・インベストメント 癌組織由来細胞塊または癌細胞凝集塊の培養方法、評価方法および保存方法
GB201100150D0 (en) * 2011-01-06 2011-02-23 Epistem Ltd Mutational analysis
WO2015195949A2 (en) 2014-06-18 2015-12-23 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) * 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer
CA3008273A1 (en) * 2015-12-18 2017-06-22 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
US12275994B2 (en) 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020235A1 (en) * 1992-04-01 1993-10-14 The Johns Hopkins University School Of Medicine Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor
AU5587998A (en) * 1996-11-15 1998-06-03 Cornell Research Foundation Inc. Activated ras interaction assay

Also Published As

Publication number Publication date
EP1898803A2 (de) 2008-03-19
EP1898803B1 (de) 2012-04-25
CA2617755A1 (en) 2007-01-04
AU2006261671A1 (en) 2007-01-04
WO2007002746A2 (en) 2007-01-04
US20070031867A1 (en) 2007-02-08
JP2009501004A (ja) 2009-01-15
EP1898803A4 (de) 2010-01-20
WO2007002746A3 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
CY1112798T1 (el) Ενωσεις διαρυλυδαντοϊνης
CY1124965T1 (el) Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
CY1120096T1 (el) Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
CY1114679T1 (el) Συνθεσεις για διαγνωση και θεραπεια ασθενειων που συνδυαζονται με παρεκκλινουσα εκφραση φουτρινων (r-σπονδινων)
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
EP2228072A4 (de) Krebsimpfstoff-zusammensetzung
Singla et al. Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies
CY1115357T1 (el) Χρηση αναστολεων πεπτιδιου του μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν τα κυτταρα για τη θεραπευτικη αγωγη διαφορων νοσηματων
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
NO20075245L (no) Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer
EP1644867A4 (de) Systeme zum identifizieren, anzeigen, markieren und behandeln verdächtiger geweberegionen
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
WO2007143752A3 (en) Targets in breast cancer for prognosis or therapy
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
EA201170139A1 (ru) 5-фенилизоксазол-3-карбоксамиды с противоопухолевыми активностями, модулирующие hsp90
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
DE602006007037D1 (de) Pyrrolotriazin-kinasehemmer
WO2007002746A3 (en) Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
ECSP077845A (es) Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
ATE534902T1 (de) Replikationsproteinn ciz1
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005089123A3 (en) Therapeutic anti-cancer dna
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type